Figure 3 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma

In vivo functional evaluation of FH FOLR1-CART in a localized U-2 OS xenograft model. A, Average radiance emitted by tumor measured over 180 days from intrafemoral tumor inoculation in mice treated with FH FOLR1-CART vs. NT T cells. B, Kaplan–Meier survival curves of xenografts treated with NT or FH FOLR1-CAR T cells. n = 2 per group. Statistical differences in survival evaluated using Mantel–Cox log-rank test. C, Bioluminescence imaging of localized U-2 OS tumor inoculated intrafemorally in mice treated with NT or FH FOLR1-CAR T cells. Radiance scale indicates progressive osteosarcoma from blue to red. *Day 13 images use a minimum radiance cutoff of 1e6 p/second/cm²/sr to show the presence of tumor engraftment prior to treatment. Minimum radiance cutoff of 2.5e6 p/second/cm²/sr used for posttreatment images to avoid noise created by excess radiance detected. X indicates death. D, day. D, Axial T2-weighted fat-saturated images of mouse femur treated with NT T cells at 84 days after local osteosarcoma cell line inoculation. Note the T2 hyperintense lobulated soft tissue mass (solid white arrow) involving the distal right femur. The bladder (star), noted more medially, also demonstrates T2 hyperintensity. E, The bone underlying the mass at 84 days after tumor cell line injection demonstrates abnormal morphology with diffuse marrow signal change and cortical destruction (open arrow). F, Axial T2-weighted fat-saturated images of mouse femur treated with FH FOLR1-CAR T cells at 84 days after tumor inoculation. Note the absence of any soft tissue mass or bone marrow signal changes of the distal right femur (solid arrows).